Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: Long-term results of the EBMT-NMAM2000 study

Blood

Volumn 121, Issue 25, 2013, Pages 5055-5063

  Gahrton, Gösta ^a   Iacobelli, Simona ^b   Björkstrand, Bo ^a   Hegenbart, Ute ^c   Gruber, Astrid ^a   Greinix, Hildegard ^d   Volin, Liisa ^e   Narni, Franco ^f   Carella, Angelo Michele ^g   Beksac, Meral ^h   Bosi, Alberto ⁱ   Milone, Giuseppe ^j   Corradini, Paolo ^k   Schönland, Stefan ^c   Friberg, Kristina ^a   Van Biezen, Anja ^l   Goldschmidt, Hartmut ^c   De Witte, Theo ^m   Morris, Curly ⁿ   Niederwieser, Dietger ^o   Garderet, Laurent ^p   Kröger, Nicolaus ^q   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h ANKARA UNIVERSITY   (Turkey)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j Ospedale Ferrarotto   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^o UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^p HÔPITAL SAINT ANTOINE   (France)

^q UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; THALIDOMIDE; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; TRANSPLANTATION CONDITIONING; AGED; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TIME; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84882446793     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-469452     Document Type: Article

References (31)

1. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9): 3474-3480.
2. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11): 1110-1120.
3. Rosiñol L, Pérez-Simón JA, Sureda A, et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591-3593.
4. Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012; 119(26):6219-6225, quiz 6399.
5. Krishnan A, Pasquini MC, Logan B, et al; Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13): 1195-1203.
6. Lokhorst H, Einsele H, Vesole D, et al; International Myeloma Working Group. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28(29):4521-4530.
7. Moreau P. Death of frontline allo-SCT in myeloma. Blood. 2012;119(26):6178-6179.
8. Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22): 3016-3022.
9. Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G. Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med. 2011;269(2): 137-147.
10. Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16): 1949-1952.
11. Bladé J, Samson D, Reece D, et al; Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123.
12. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26(24):4505-4519.
13. Logan BR, Klein JP, Zhang MJ. Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation. Biometrics. 2008;64(3):733-740.
14. Roos-Weil D, Moreau P, Avet-Loiseau H, et al; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica. 2011;96(10): 1504-1511.
15. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3): 1196-1198.
16. Aschan J, Lönnqvist B, Ringdén O, Kumlien G, Gahrton G. Graft-versus-myeloma effect. Lancet. 1996;348(9023):346.
17. Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. 2009;113(14):3135-3136.
18. Kröger N, Zabelina T, Berger J, et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia. 2011;25(10):1657-1661.
19. Kröger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48(3):403-407.
20. Efebera YA, Qureshi SR, Cole SM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010;16(8):1122-1129.
21. Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 2012;18(4):617-626.
22. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475-2482.
23. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010;28(7):1209-1214.
24. Cavo M, Pantani L, Petrucci MT, et al; GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9-19.
25. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-959.
26. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1770-1781.
27. Cavo M, Rajkumar SV, Palumbo A, et al; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23): 6063-6073.
28. Attal M, Lauwers-Cances V, Marit G, et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
29. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012;30(26):3202-3208.
30. Giralt S. Graft-versus-host disease: have we solved the problem? J Clin Oncol. 2012;30(26): 3160-3161.
31. Bensinger W, Green D, Burwick N, Becker P. Lenalidomide Is Effective Therapy for Relapse After Allogeneic Stem Cell Transplant for Multiple Myeloma In: ASH 54th Annual Meeting. Atlanta Ga: Blood 2012; 120/21 Abstract 3064.